{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:23:48Z","timestamp":1792783428675,"version":"4.5.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T00:00:00Z","timestamp":1632441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T00:00:00Z","timestamp":1632441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National Cancer Institute","award":["P50CA107399"],"award-info":[{"award-number":["P50CA107399"]}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["LLS TRP 6611-20"],"award-info":[{"award-number":["LLS TRP 6611-20"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s12185-021-03215-6","type":"journal-article","created":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T17:39:13Z","timestamp":1632505153000},"page":"544-553","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Development of CMV-CD19 bi-specific CAR T cells with post-infusion in vivo boost using an anti-CMV vaccine"],"prefix":"10.1007","volume":"114","author":[{"given":"Xiuli","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don J.","family":"Diamond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Forman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryotaro","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,24]]},"reference":[{"issue":"5","key":"3215_CR1","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439\u201348.","journal-title":"N Engl J Med"},{"key":"3215_CR2","unstructured":"Novartis. Kymriah full prescribing information: (2018) https:\/\/www.hcp.novartis.com\/products\/kymriah\/?site=KYDDAY0HCPBR0051&source=01030&gclid=CjwKCAiAnfjyBRBxEiwA-EECLCt32mN2lFc2bxerK8KSKR5YLKRXKzGnrwCx4kaKhBfWVNb76oFZthoCWkwQAvD_BwE&gclsrc=aw.ds."},{"issue":"26","key":"3215_CR3","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","volume":"377","author":"SJ Schuster","year":"2017","unstructured":"Schuster SJ, Svoboda J, Chong EA, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017;377(26):2545\u201354.","journal-title":"N Engl J Med"},{"issue":"26","key":"3215_CR4","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory Large B-cell lymphoma. N Engl J Med. 2017;377(26):2531\u201344.","journal-title":"N Engl J Med"},{"key":"3215_CR5","unstructured":"Kite Pharma I. Yescarta; (2020): https:\/\/getstartedwithyescarta.com\/?gclid=CjwKCAiAnfjyBRBxEiwA-EECLId8Sq2WSYUV4wMRB19lf4eFPnYRh_oPd8oYqgSZdfWNJIRe9BQrLRoC14UQAvD_BwE."},{"issue":"1","key":"3215_CR6","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1182\/blood-2016-07-729756","volume":"129","author":"C La Rosa","year":"2017","unstructured":"La Rosa C, Longmate J, Martinez J, et al. MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults. Blood. 2017;129(1):114\u201325.","journal-title":"Blood"},{"key":"3215_CR7","doi-asserted-by":"publisher","DOI":"10.7326\/m19-2511","author":"I Aldoss","year":"2020","unstructured":"Aldoss I, La Rosa C, Baden LR, et al. Poxvirus vectored cytomegalovirus vaccine to prevent cytomegalovirus viremia in transplant recipients: a phase 2, randomized clinical trial. Ann Intern Med. 2020. https:\/\/doi.org\/10.7326\/m19-2511.","journal-title":"Ann Intern Med"},{"key":"3215_CR8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-14-2920","author":"X Wang","year":"2015","unstructured":"Wang X, Wong CW, Urak R, et al. CMVpp65 vaccine enhances the antitumor efficacy of adoptively transferred CD19-redirected CMV-specific T cells. Clin Cancer Res. 2015. https:\/\/doi.org\/10.1158\/1078-0432.ccr-14-2920.","journal-title":"Clin Cancer Res"},{"issue":"24","key":"3215_CR9","doi-asserted-by":"publisher","first-page":"6175","DOI":"10.1158\/1078-0432.CCR-18-0758","volume":"24","author":"KT Mueller","year":"2018","unstructured":"Mueller KT, Waldron E, Grupp SA, et al. Clinical Pharmacology of tisagenlecleucel in B-cell acute lymphoblastic leukemia. Clin Cancer Res. 2018;24(24):6175\u201384.","journal-title":"Clin Cancer Res"},{"issue":"16","key":"3215_CR10","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509\u201318.","journal-title":"N Engl J Med"},{"issue":"95","key":"3215_CR11","doi-asserted-by":"publisher","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","volume":"3","author":"M Kalos","year":"2011","unstructured":"Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3(95):95ra73.","journal-title":"Sci Transl Med"},{"issue":"177","key":"3215_CR12","doi-asserted-by":"publisher","first-page":"177ra138","DOI":"10.1126\/scitranslmed.3005930","volume":"5","author":"RJ Brentjens","year":"2013","unstructured":"Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5(177):177ra138.","journal-title":"Sci Transl Med"},{"issue":"12","key":"3215_CR13","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","volume":"119","author":"JN Kochenderfer","year":"2012","unstructured":"Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012;119(12):2709\u201320.","journal-title":"Blood"},{"issue":"6","key":"3215_CR14","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1097\/CCO.0000000000000232","volume":"27","author":"SJ Priceman","year":"2015","unstructured":"Priceman SJ, Forman SJ, Brown CE. Smart CARs engineered for cancer immunotherapy. Curr Opin Oncol. 2015;27(6):466\u201374.","journal-title":"Curr Opin Oncol"},{"issue":"11","key":"3215_CR15","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1182\/blood-2016-07-730689","volume":"128","author":"DW Lee","year":"2016","unstructured":"Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014; 124(2): 188\u2013195. Blood. 2016;128(11):1533 (Erratum).","journal-title":"Blood"},{"issue":"Suppl 1","key":"3215_CR16","first-page":"S32","volume":"33","author":"W van der Bij","year":"2001","unstructured":"van der Bij W, Speich R. Management of cytomegalovirus infection and disease after solid-organ transplantation. Clin Infect Dis. 2001;33(Suppl 1):S32-37.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"3215_CR17","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1365-2796.2006.01618.x","volume":"259","author":"C Soderberg-Naucler","year":"2006","unstructured":"Soderberg-Naucler C. Does cytomegalovirus play a causative role in the development of various inflammatory diseases and cancer? J Intern Med. 2006;259(3):219\u201346.","journal-title":"J Intern Med"},{"issue":"16","key":"3215_CR18","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1056\/NEJM199510193331603","volume":"333","author":"EA Walter","year":"1995","unstructured":"Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995;333(16):1038\u201344.","journal-title":"N Engl J Med"},{"issue":"19","key":"3215_CR19","doi-asserted-by":"publisher","first-page":"4283","DOI":"10.1182\/blood-2009-07-232454","volume":"114","author":"AM Leen","year":"2009","unstructured":"Leen AM, Christin A, Myers GD, et al. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood. 2009;114(19):4283\u201392.","journal-title":"Blood"},{"issue":"3","key":"3215_CR20","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.bbmt.2003.09.017","volume":"10","author":"CM Bollard","year":"2004","unstructured":"Bollard CM, Kuehnle I, Leen A, Rooney CM, Heslop HE. Adoptive immunotherapy for posttransplantation viral infections. Biol Blood Marrow Transplant. 2004;10(3):143\u201355.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"3215_CR21","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-1759(90)90210-M","volume":"128","author":"SR Riddell","year":"1990","unstructured":"Riddell SR, Greenberg PD. The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J Immunol Methods. 1990;128(2):189\u2013201.","journal-title":"J Immunol Methods"},{"issue":"5067","key":"3215_CR22","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1126\/science.1352912","volume":"257","author":"SR Riddell","year":"1992","unstructured":"Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science. 1992;257(5067):238\u201341.","journal-title":"Science"},{"issue":"11","key":"3215_CR23","doi-asserted-by":"publisher","first-page":"3916","DOI":"10.1182\/blood.V99.11.3916","volume":"99","author":"H Einsele","year":"2002","unstructured":"Einsele H, Roosnek E, Rufer N, et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood. 2002;99(11):3916\u201322.","journal-title":"Blood"},{"issue":"15","key":"3215_CR24","doi-asserted-by":"publisher","first-page":"4965","DOI":"10.1073\/pnas.81.15.4965","volume":"81","author":"H Pande","year":"1984","unstructured":"Pande H, Baak SW, Riggs AD, Clark BR, Shively JE, Zaia JA. Cloning and physical mapping of a gene fragment coding for a 64-kilodalton major late antigen of human cytomegalovirus. Proc Natl Acad Sci USA. 1984;81(15):4965\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"3215_CR25","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.4049\/jimmunol.134.5.3391","volume":"134","author":"SJ Forman","year":"1985","unstructured":"Forman SJ, Zaia JA, Clark BR, et al. A 64,000 dalton matrix protein of human cytomegalovirus induces in vitro immune responses similar to those of whole viral antigen. J Immunol. 1985;134(5):3391\u20135.","journal-title":"J Immunol"},{"issue":"1","key":"3215_CR26","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/jmv.1890430119","volume":"43","author":"E McLaughlin-Taylor","year":"1994","unstructured":"McLaughlin-Taylor E, Pande H, Forman SJ, et al. Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes. J Med Virol. 1994;43(1):103\u201310.","journal-title":"J Med Virol"},{"issue":"5","key":"3215_CR27","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1182\/blood.V90.5.1751","volume":"90","author":"DJ Diamond","year":"1997","unstructured":"Diamond DJ, York J, Sun JY, Wright CL, Forman SJ. Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood. 1997;90(5):1751\u201367.","journal-title":"Blood"},{"issue":"8","key":"3215_CR28","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1093\/infdis\/jis107","volume":"205","author":"C La Rosa","year":"2012","unstructured":"La Rosa C, Longmate J, Lacey SF, et al. Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant. J Infect Dis. 2012;205(8):1294\u2013304.","journal-title":"J Infect Dis"},{"key":"3215_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00246-X","author":"R Nakamura","year":"2016","unstructured":"Nakamura R, Rosa CL, Longmate J, et al. Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial. Lancet Haematol. 2016. https:\/\/doi.org\/10.1016\/S2352-3026(15)00246-X.","journal-title":"Lancet Haematol"},{"issue":"9","key":"3215_CR30","first-page":"322","volume":"112","author":"A Mayr","year":"1999","unstructured":"Mayr A. Historical review of smallpox, the eradication of smallpox and the attenuated smallpox MVA vaccine. Berl Munch Tierarztl Wochenschr. 1999;112(9):322\u20138.","journal-title":"Berl Munch Tierarztl Wochenschr"},{"issue":"5\u20136","key":"3215_CR31","first-page":"375","volume":"167","author":"A Mayr","year":"1978","unstructured":"Mayr A, Stickl H, Muller HK, Danner K, Singer H. The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author\u2019s transl). Zentralbl Bakteriol [B]. 1978;167(5\u20136):375\u201390.","journal-title":"Zentralbl Bakteriol [B]"},{"issue":"8","key":"3215_CR32","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/j.vaccine.2006.10.047","volume":"25","author":"J Parrino","year":"2007","unstructured":"Parrino J, McCurdy LH, Larkin BD, et al. Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax((R)) challenge in vaccinia-naive and vaccinia-immune individuals. Vaccine. 2007;25(8):1513\u201325.","journal-title":"Vaccine"},{"issue":"9","key":"3215_CR33","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1086\/651561","volume":"201","author":"MB Wilck","year":"2010","unstructured":"Wilck MB, Seaman MS, Baden LR, et al. Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration. J Infect Dis. 2010;201(9):1361\u201370.","journal-title":"J Infect Dis"},{"issue":"9","key":"3215_CR34","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1086\/651560","volume":"201","author":"MS Seaman","year":"2010","unstructured":"Seaman MS, Wilck MB, Baden LR, et al. Effect of vaccination with modified vaccinia Ankara (ACAM3000) on subsequent challenge with Dryvax. J Infect Dis. 2010;201(9):1353\u201360.","journal-title":"J Infect Dis"},{"issue":"21","key":"3215_CR35","doi-asserted-by":"publisher","first-page":"4554","DOI":"10.1016\/j.vaccine.2005.08.048","volume":"24","author":"SC Gilbert","year":"2006","unstructured":"Gilbert SC, Moorthy VS, Andrews L, et al. Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis. Vaccine. 2006;24(21):4554\u201361.","journal-title":"Vaccine"},{"issue":"8","key":"3215_CR36","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1086\/378515","volume":"188","author":"VS Moorthy","year":"2003","unstructured":"Moorthy VS, Pinder M, Reece WH, et al. Safety and immunogenicity of DNA\/modified vaccinia virus ankara malaria vaccination in African adults. JInfectDis. 2003;188(8):1239\u201344.","journal-title":"JInfectDis"},{"issue":"7","key":"3215_CR37","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1097\/CJI.0b013e3181ace876","volume":"32","author":"RJ Amato","year":"2009","unstructured":"Amato RJ, Shingler W, Goonewardena M, et al. Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFN-alpha): a phase 2 trial. J Immunother. 2009;32(7):765\u201372.","journal-title":"J Immunother"},{"issue":"8","key":"3215_CR38","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1002\/jgm.397","volume":"5","author":"C Rochlitz","year":"2003","unstructured":"Rochlitz C, Figlin R, Squiban P, et al. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J Gene Med. 2003;5(8):690\u20139.","journal-title":"J Gene Med"},{"issue":"1","key":"3215_CR39","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0264-410X(03)00538-3","volume":"22","author":"A Cosma","year":"2003","unstructured":"Cosma A, Nagaraj R, Buhler S, et al. Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals. Vaccine. 2003;22(1):21\u20139.","journal-title":"Vaccine"},{"issue":"33","key":"3215_CR40","doi-asserted-by":"publisher","first-page":"4468","DOI":"10.1016\/j.vaccine.2009.05.018","volume":"27","author":"L Gudmundsdotter","year":"2009","unstructured":"Gudmundsdotter L, Nilsson C, Brave A, et al. Recombinant modified vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity. Vaccine. 2009;27(33):4468\u201374.","journal-title":"Vaccine"},{"issue":"9","key":"3215_CR41","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/nrc1167","volume":"3","author":"ME Dudley","year":"2003","unstructured":"Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer. 2003;3(9):666\u201375.","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"3215_CR42","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1200\/JCO.2005.00.240","volume":"23","author":"ME Dudley","year":"2005","unstructured":"Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23(10):2346\u201357.","journal-title":"J Clin Oncol"},{"issue":"11","key":"3215_CR43","doi-asserted-by":"publisher","first-page":"5535","DOI":"10.1128\/JVI.78.11.5535-5545.2004","volume":"78","author":"EJ Wherry","year":"2004","unstructured":"Wherry EJ, Ahmed R. Memory CD8 T-cell differentiation during viral infection. J Virol. 2004;78(11):5535\u201345.","journal-title":"J Virol"},{"issue":"11","key":"3215_CR44","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1182\/blood-2011-08-371971","volume":"119","author":"E Doubrovina","year":"2012","unstructured":"Doubrovina E, Oflaz-Sozmen B, Prockop SE, et al. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood. 2012;119(11):2644\u201356.","journal-title":"Blood"},{"issue":"11","key":"3215_CR45","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/nm.1882","volume":"14","author":"MA Pule","year":"2008","unstructured":"Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008;14(11):1264\u201370.","journal-title":"Nat Med"},{"issue":"7","key":"3215_CR46","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1182\/blood-2006-11-059139","volume":"110","author":"B Savoldo","year":"2007","unstructured":"Savoldo B, Rooney CM, Di Stasi A, et al. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood. 2007;110(7):2620\u201330.","journal-title":"Blood"},{"issue":"6","key":"3215_CR47","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1182\/blood.V99.6.2009","volume":"99","author":"C Rossig","year":"2002","unstructured":"Rossig C, Bollard CM, Nuchtern JG, Rooney CM, Brenner MK. Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood. 2002;99(6):2009\u201316.","journal-title":"Blood"},{"issue":"4","key":"3215_CR48","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1182\/blood-2004-03-1208","volume":"105","author":"LJ Cooper","year":"2005","unstructured":"Cooper LJ, Al-Kadhimi Z, Serrano LM, et al. Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1. Blood. 2005;105(4):1622\u201331.","journal-title":"Blood"},{"issue":"17","key":"3215_CR49","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1182\/blood-2013-06-506741","volume":"122","author":"CR Cruz","year":"2013","unstructured":"Cruz CR, Micklethwaite KP, Savoldo B, et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood. 2013;122(17):2965\u201373.","journal-title":"Blood"},{"issue":"24","key":"3215_CR50","doi-asserted-by":"publisher","first-page":"7340","DOI":"10.1158\/1078-0432.CCR-18-3199","volume":"25","author":"N Lapteva","year":"2019","unstructured":"Lapteva N, Gilbert M, Diaconu I, et al. T-cell receptor Stimulation enhances the expansion and function of CD19 chimeric antigen receptor-expressing T cells. Clin Cancer Res. 2019;25(24):7340\u201350.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"3215_CR51","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1182\/blood.V92.5.1549.417k32_1549_1555","volume":"92","author":"CM Rooney","year":"1998","unstructured":"Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998;92(5):1549\u201355.","journal-title":"Blood"},{"issue":"10","key":"3215_CR52","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/nm1475","volume":"12","author":"AM Leen","year":"2006","unstructured":"Leen AM, Myers GD, Sili U, et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med. 2006;12(10):1160\u20136.","journal-title":"Nat Med"},{"issue":"8","key":"3215_CR53","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1038\/mt.2012.130","volume":"20","author":"U Gerdemann","year":"2012","unstructured":"Gerdemann U, Keirnan JM, Katari UL, et al. Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections. Mol Ther. 2012;20(8):1622\u201332.","journal-title":"Mol Ther"},{"issue":"242","key":"3215_CR54","doi-asserted-by":"publisher","first-page":"242ra283","DOI":"10.1126\/scitranslmed.3008825","volume":"6","author":"A Papadopoulou","year":"2014","unstructured":"Papadopoulou A, Gerdemann U, Katari UL, et al. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med. 2014;6(242):242ra283.","journal-title":"Sci Transl Med"},{"issue":"20","key":"3215_CR55","doi-asserted-by":"publisher","first-page":"4360","DOI":"10.1182\/blood-2010-01-262089","volume":"116","author":"T Feuchtinger","year":"2010","unstructured":"Feuchtinger T, Opherk K, Bethge WA, et al. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood. 2010;116(20):4360\u20137.","journal-title":"Blood"},{"issue":"2","key":"3215_CR56","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1097\/CJI.0b013e318209c94c","volume":"34","author":"O Itzhaki","year":"2011","unstructured":"Itzhaki O, Hovav E, Ziporen Y, et al. Establishment and large-scale expansion of minimally cultured \u201cyoung\u201d tumor infiltrating lymphocytes for adoptive transfer therapy. J Immunother. 2011;34(2):212\u201320.","journal-title":"J Immunother"},{"issue":"13","key":"3215_CR57","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1093\/jnci\/83.13.932","volume":"83","author":"P Aebersold","year":"1991","unstructured":"Aebersold P, Hyatt C, Johnson S, et al. Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: association with clinical response. J Natl Cancer Inst. 1991;83(13):932\u20137.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"3215_CR58","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1097\/01.cji.0000211321.07654.b8","volume":"30","author":"X Shen","year":"2007","unstructured":"Shen X, Zhou J, Hathcock KS, et al. Persistence of tumor infiltrating lymphocytes in adoptive immunotherapy correlates with telomere length. J Immunother. 2007;30(1):123\u20139.","journal-title":"J Immunother"},{"issue":"Supplement_1","key":"3215_CR59","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.1182\/blood-2019-131843","volume":"134","author":"X Wang","year":"2019","unstructured":"Wang X, Walter M, Urak R, et al. Large-scale manufacturing of CMV-CD19CAR T cells and characterization of their biologic and immunologic properties. Blood. 2019;134(Supplement_1):3247\u20133247.","journal-title":"Blood"},{"issue":"4","key":"3215_CR60","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1159\/000088416","volume":"114","author":"PL Zinzani","year":"2005","unstructured":"Zinzani PL. Autologous hematopoietic stem cell transplantation in Non-Hodgkin\u2019s lymphomas. Acta Haematol. 2005;114(4):255\u20139.","journal-title":"Acta Haematol"},{"issue":"23","key":"3215_CR61","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","volume":"333","author":"T Philip","year":"1995","unstructured":"Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma. N Engl J Med. 1995;333(23):1540\u20135.","journal-title":"N Engl J Med"},{"issue":"27","key":"3215_CR62","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","volume":"28","author":"C Gisselbrecht","year":"2010","unstructured":"Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184\u201390.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3215_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/bmt.2013.72","volume":"49","author":"E Klyuchnikov","year":"2014","unstructured":"Klyuchnikov E, Bacher U, Kroll T, et al. Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how? Bone Marrow Transplant. 2014;49(1):1\u20137.","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"3215_CR64","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.bbmt.2009.08.011","volume":"16","author":"HM Lazarus","year":"2010","unstructured":"Lazarus HM, Zhang MJ, Carreras J, et al. A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR. Biol Blood Marrow Transplant. 2010;16(1):35\u201345.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"3215_CR65","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.bbmt.2006.05.018","volume":"12","author":"I Aksentijevich","year":"2006","unstructured":"Aksentijevich I, Jones RJ, Ambinder RF, Garrett-Mayer E, Flinn IW. Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin\u2019s lymphoma. Biol Blood Marrow Transplant. 2006;12(9):965\u201372.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"3215_CR66","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/j.1365-2141.2005.05755.x","volume":"131","author":"RT Doocey","year":"2005","unstructured":"Doocey RT, Toze CL, Connors JM, et al. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma. Br J Haematol. 2005;131(2):223\u201330.","journal-title":"Br J Haematol"},{"issue":"6","key":"3215_CR67","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s00277-011-1395-9","volume":"91","author":"L Rigacci","year":"2012","unstructured":"Rigacci L, Puccini B, Dodero A, et al. Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study. Ann Hematol. 2012;91(6):931\u20139.","journal-title":"Ann Hematol"},{"issue":"20","key":"3215_CR68","doi-asserted-by":"publisher","first-page":"4256","DOI":"10.1182\/blood-2012-06-436725","volume":"120","author":"U Bacher","year":"2012","unstructured":"Bacher U, Klyuchnikov E, Le-Rademacher J, et al. Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity? Blood. 2012;120(20):4256\u201362.","journal-title":"Blood"},{"issue":"10","key":"3215_CR69","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1200\/JCO.2010.30.2596","volume":"29","author":"RJ van Kampen","year":"2011","unstructured":"van Kampen RJ, Canals C, Schouten HC, et al. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin\u2019s lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European group for blood and marrow transplantation registry. J Clin Oncol. 2011;29(10):1342\u20138.","journal-title":"J Clin Oncol"},{"issue":"3","key":"3215_CR70","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1200\/JCO.2008.17.3328","volume":"27","author":"KJ Thomson","year":"2009","unstructured":"Thomson KJ, Morris EC, Bloor A, et al. Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2009;27(3):426\u201332.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3215_CR71","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.bbmt.2009.09.002","volume":"16","author":"A Sirvent","year":"2010","unstructured":"Sirvent A, Dhedin N, Michallet M, et al. Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Biol Blood Marrow Transplant. 2010;16(1):78\u201385.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"24","key":"3215_CR72","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1182\/blood-2015-12-686725","volume":"127","author":"X Wang","year":"2016","unstructured":"Wang X, Popplewell LL, Wagner JR, et al. Phase 1 studies of central memory\u2013derived CD19 CAR T\u2013cell therapy following autologous HSCT in patients with B-cell NHL. Blood. 2016;127(24):2980\u201390.","journal-title":"Blood"},{"key":"3215_CR73","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.615424","author":"S Nishiwaki","year":"2011","unstructured":"Nishiwaki S, Miyamura K. Allogeneic stem cell transplantation for adult philadelphia chromosome-negative acute lymphoblastic leukemia. Leuk Lymphoma. 2011. https:\/\/doi.org\/10.3109\/10428194.2011.615424.","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"3215_CR74","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.3324\/haematol.2016.144311","volume":"101","author":"N Gokbuget","year":"2016","unstructured":"Gokbuget N, Dombret H, Ribera JM, et al. International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed\/refractory acute lymphoblastic leukemia. Haematologica. 2016;101(12):1524\u201333.","journal-title":"Haematologica"},{"issue":"3","key":"3215_CR75","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","volume":"109","author":"AK Fielding","year":"2007","unstructured":"Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study. Blood. 2007;109(3):944\u201350.","journal-title":"Blood"},{"issue":"Suppl 1","key":"3215_CR76","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.1182\/blood-2018-99-119883","volume":"132","author":"SK Khaled","year":"2018","unstructured":"Khaled SK, Blanchard S, Wang X, et al. Adult patients with ALL treated with CD62L+ T na\u00efve\/memory-enriched T cells expressing a CD19-CAR mediate potent antitumor activity with a low toxicity profile. Blood. 2018;132(Suppl 1):4016\u20134016.","journal-title":"Blood"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-021-03215-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-021-03215-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-021-03215-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T22:55:51Z","timestamp":1744152951000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-021-03215-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,24]]},"references-count":76,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["3215"],"URL":"https:\/\/doi.org\/10.1007\/s12185-021-03215-6","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,24]]},"assertion":[{"value":"25 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Xiuli Wang: No conflict of interest relevant to this work. Don J. Diamond: Helocyte for royalties and research support. Stephen J. Forman: No conflict of interest relevant to this work. Ryotaro Nakamura: Helocyte for research support.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}